TPST (Tempest Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $1.12
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Net Margin %?

Tempest Therapeutics TPST 32 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Tempest Therapeutics ranks worse than 106044.43% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Tempest Therapeutics's Net Income for the three months ended in Mar. 2026 was $-27.70 Mil. Tempest Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Tempest Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Tempest Therapeutics's Net Margin % or its related term are showing as below:


TPST's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Tempest Therapeutics  (NAS:TPST) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Tempest Therapeutics Net Margin % Related Terms

Tempest Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Net Margin % Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tempest Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TPST vs HOWL, INTI, GTBP: Net Margin % Comparison

For the Biotechnology subindustry, Tempest Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Net Margin % falls into.


TPST
32GF Score
Tempest Therapeutics Inc TPST
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Tempest Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-26.262/0
= %

Tempest Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-27.696/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Tempest Therapeutics (TPST) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry.
Is Tempest Therapeutics' Net Margin % too high?
Tempest Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Tempest Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Net Margin % compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #999999 out of 943 companies for Net Margin %. This places Tempest Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price